Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AASLD, adaptive, allergic, allosteric, amendsAccounting, Angiotension, ASPIRE, Australia, Bahrain, Baxter, bioequivalence, bowel, bulk, buyer, choose, consecutive, converged, customer, downstream, enterprise, environment, exhausted, extreme, fewer, flexibility, floating, Focal, front, gout, Hospira, hypothetical, IASB, implied, improper, India, innate, intelligently, interactive, Joinder, Journal, language, Lawrence, leaving, LIBOR, lived, Lundbeck, maker, margin, Mitgation, mitigating, mortality, nontransferable, objection, PDUFA, physiology, PII, PIII, pivitol, pivotal, prepaid, prime, proteinuria, qualitative, reassessed, recovery, Region, regularly, relapsed, remediating, Remediation, remote, resistant, resource, Retrophin, retrospectively, revolving, SAGE, Singapore, skilled, sNDA, Somaxon, staffing, Taiwan, text, tied, title, Turkey, unchanged, Union, User, verify, viability, Wall, XBRL
Removed:
administer, advancement, anabolic, androgen, announcement, ascending, attributable, BMS, bone, breast, cachexia, capable, Catalent, CEO, CFO, chargeback, chosen, collaboratively, collectibility, combinatorial, commenced, communicated, consisted, consulting, continually, convenient, costly, coupled, dedicated, demonstration, dermatological, distinct, distinction, divided, dosing, dysfunction, employing, encoded, encoding, equivalent, estimating, factoring, financially, frailty, gel, GPCR, handled, healthy, historically, hypogonadism, immunological, implementation, importantly, inclusion, inflammation, inhibitor, initiated, insolvency, insolvent, introduced, Investigational, issuing, joint, kinase, library, managed, MAP, materialize, Medicaid, moderate, modulate, momentum, ocular, offered, optimization, Panretin, paradigm, partial, petition, Plough, Polymeric, preliminary, processed, processing, prospective, prostate, protein, purpose, RA, rapid, rebate, released, rotation, SARM, schedule, screen, selectively, servicing, sexual, skeletal, sublicensee, survive, therefrom, throughput, topical, transition, Trevena, typically, unspecified, utility, vendor, wide, wrote
Filing tables
Filing exhibits
- 10-K Annual report
- 10.130 Joinder and Second Amendment to Loan and Security Agreement
- 10.131 License Agreement
- 10.132 Supply Agreement
- 10.133 License and Supply Agreement
- 10.134 Fourth Amendment to Loan and Security Agreement
- 21.1 Subsidiaries of Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification by Principal Executive Officer
- 31.2 Certification by Principal Financial Officer
- 32.1 Certification by Principal Executive Officer
- 32.2 Certification by Principal Financial Officer
Related press release
LGND similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our reports dated February 23, 2012 with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Ligand Pharmaceuticals Incorporated on Form 10-K for the year ended December 31, 2011. We hereby consent to the incorporation by reference of said reports in the Registration Statements of Ligand Pharmaceuticals, Incorporated on Form S-3 (File No. 333-177338, effective October 26, 2011) and Forms S-8 (File No. 333-160132, effective June 22, 2009 and File No. 333-131029, effective June 18, 2007).
/s/ GRANT THORNTON LLP
San Diego, California
February 23, 2012